Healthcare | June 24, 2025
Biocon Biologics collaborates with National Cancer Society Malaysia
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The transaction is expected to close in Q2 FY 2026
The company will provide the necessary response to USFDA within stipulated 15 days
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing plants by volume
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
The company received seven observations in the Form-483
Subscribe To Our Newsletter & Stay Updated
